Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment ...

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

1 Day RANI 5.67% DJIA 0.30% Russell 2K -0.61% Health Care/Life Sciences -1.75% ...

The Union of B.C. Indian Chiefs said in a statement that the answer to the Northern Gateway pipeline from Alberta to the Pacific "is still no," after Alberta Premier Danielle Smith suggested ...